Building an Immune-Related Genes Model to Predict Treatment, Extracellular Matrix, and Prognosis of Head and Neck Squamous Cell Carcinoma

Figure 7

Exploration of ICIs therapeutics in different risk groups: (a) TIDE, MSI, T-cell exclusion, and dysfunction score in distinct groups; (b) ROC analysis of the IRGs prognostic model, TIDE, and TIS on 3-year and ROC analysis of the model in 1-, 2-, and 3-year; (c) differences of IC₅₀ of chemotherapeutics among different groups.

(a)

(b)

(c)